Residual Exacerbations With Mepolizumab

NCT04578171 · tracked via the Priya Life Science Canada tracker

Sponsor

Laval University

Phase

Observational

Started

2021-07-06

Last updated

2025-02-10

Condition(s) studied

Asthma

Investigational drug(s) / intervention(s)

Mepolizumab →

Mepolizumab: 100 mg subcutaneous injections every four weeks

Study summary

This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.

Eligibility

Sex

ALL

Min age

18 Years

Max age

90 Years

Healthy volunteers

Inclusion Criteria: * With a proven diagnosis of severe asthma as defined by the Canadian Thoracic Society * Eligible for mepolizumab treatment * Able and willing to sign the informed consent form Exclusion Criteria: * Any respiratory disease apart from asthma * Confounding comorbidities sur as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome

Primary outcome measure(s)

Proportion of eosinophilic vs non-eosinophilic remaining exacerbation during the treatment period — Between baseline and month 24
Eosinophilic exacerbation defined as \>=3% sputum eosinophils. Ratio of eosinophilic vs non eosinophilic asthma exacerbation

Trial sites (1)

Facility	City	Region	Status
Institut universitaire de cardiologie et de pneumologie de Québec	Québec	Quebec	Recruiting

On this site

📄 Nucala (mepolizumab) drug profile →

More Laval University trials in Canada

Effects of Cranberry on Gut and Metabolic Health Recruiting

Potential Impact of the Use of the Application VentilO Active, not recruiting

Reducing Low-value Care for Trauma Admissions Starting soon

Impact of Ultra-processed Foods on Cardiometabolic Risk Factors Recruiting

Radial Artery Occlusion and Dual Artery Hemostasis After Transradial Approach. Recruiting

Other trials for the same condition

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study Active, not recruiting

Canadian Consortium on Airway Mucus Occlusions in Asthma, COPD and Chronic Cough Recruiting

Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Active, not recruiting

Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma Active, not recruiting

Testing the Effects of Temperature & Humidity on Children With and Without Asthma in an Environmental Climatic Chamber Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04578171 on ClinicalTrials.gov ↗ ← All trials in Canada